首页 | 本学科首页   官方微博 | 高级检索  
     


CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial
Affiliation:1. Chronic Disease Research Institute, The Children''s Hospital, and National Clinical Research Center for Child Health, School of Public Health, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China;2. Department of Nutrition and Food Hygiene, School of Public Health, Zhejiang University, Hangzhou, Zhejiang, China;3. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden;4. Department of Laboratory Medicine, Clinical Pharmacology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden;5. Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK;6. Department of Oncology, South General Hospital, Stockholm, Sweden;7. Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden;8. Department of Neurobiology, Care Science and Society, Division of Nursing and Theme Cancer, Karolinska University Hospital, Stockholm, Sweden;9. Department of Oncology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark;10. Department of Clinical Sciences Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden
Abstract:
Keywords:CYP2D6 genotype  tamoxifen  treatment discontinuation  mammographic density  breast cancer
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号